keyword
https://read.qxmd.com/read/36843558/use-of-optimal-medical-therapy-in-patients-with-diabetes-and-atherosclerotic-cardiovascular-disease-insights-from-a-prospective-longitudinal-cohort-study
#21
JOURNAL ARTICLE
Suzanne V Arnold, James A de Lemos, Luke Zheng, Robert S Rosenson, Christie M Ballantyne, Shushama Alam, Deepak L Bhatt, Christopher P Cannon, Mikhail Kosiborod
AIM: To examine improvement in the use of optimal medical therapy (OMT) for secondary prevention in patients with atherosclerotic cardiovascular disease (ASCVD) and diabetes. MATERIALS AND METHODS: Patients with ASCVD (coronary, cerebrovascular, peripheral) and low-density lipoprotein-cholesterol of 70 mg/dl or higher were enrolled from December 2016 to July 2018 from 107 US sites/physicians (47% cardiology, 41% primary care, 12% other) and prospectively followed for 2 years (current analysis restricted to subgroup with diabetes)...
February 27, 2023: Diabetes, Obesity & Metabolism
https://read.qxmd.com/read/36779380/gender-differences-in-risk-factor-management-and-pharmacological-treatment-among-chd-patients-belgian-results-of-the-euroaspire-iv-and-euroaspire-v-surveys
#22
JOURNAL ARTICLE
Pieter Vynckier, Johan De Sutter, Michel De Pauw, Hans Vandekerckhove, Guy De Backer, Pieter Vervaet, Nancy Deweerdt, Paul Dendale, Alexandre Persu, Arne Janssen, Patrick Chenu, Kornelia Kotseva, Sofie Gevaert, Dirk De Bacquer, Delphine De Smedt
AIMS: The aim of this study was to provide an up-to-date overview of gender differences or similarities in risk factor control and medical management in the Belgian CHD population. METHODS: All analyses are based on the ESC EORP EUROASPIRE IV and EUROASPIRE V (European Survey Of Cardiovascular Disease Prevention And Diabetes) surveys. Patients between 18 and 80 years old, hospitalised for a first or recurrent coronary event, were included in the survey. RESULTS: Data were available for 10,519 patients, of which 23...
February 13, 2023: Acta Cardiologica
https://read.qxmd.com/read/36739654/novel-biomarkers-and-emerging-tools-to-identify-causal-molecular-pathways-in-hypertension-and-associated-cardiovascular-diseases
#23
JOURNAL ARTICLE
Ewelina Józefczuk, Tomasz J Guzik, Mateusz Siedlinski
Hypertension (HT) is a modifiable risk factor for life-threatening cardiovascular diseases (CVDs) including coronary artery disease, heart failure, or stroke. Despite significant progress in understanding the pathophysiological mechanisms of the disease, the molecular pathways targeted by HT treatment remain largely unchanged. This warrants the need for finding novel biomarkers, which are causally related to persistent high blood pressure (BP) and may be pharmacologically targeted. Analytical output derived from large-scale biobanks, containing high-throughput genetic and biochemical data, such as OLINK and SomaScan-based proteomics or Nuclear Magnetic Resonance-based metabolomics, as well as novel analytical tools including the Mendelian randomization (MR) approach, enabling genetic causal inference, may create new treatment opportunities for HT and related CVDs...
2023: Kardiologia Polska
https://read.qxmd.com/read/36455667/revisiting-secondary-prevention-in-coronary-heart-disease
#24
REVIEW
Alben Sigamani, Rajeev Gupta
Secondary prevention in coronary heart disease is the prevention of occurrence of recurrent coronary events after clinical diagnosis. High level of adherence to secondary prevention interventions, especially aggressive lifestyle changes and pharmacotherapy can lead to significant decline in recurrent coronary events. Both international and Indian studies have reported low adherence to such therapies. Evidence-based useful interventions include regular physical activity, yoga, intake of healthy diet, smoking and tobacco use cessation and weight management...
2022: Indian Heart Journal
https://read.qxmd.com/read/36279931/coordinating-cardiology-clinics-randomized-trial-of-interventions-to-improve-outcomes-coordinate-diabetes-rationale-and-design
#25
JOURNAL ARTICLE
Adam J Nelson, Neha J Pagidipati, Michelle D Kelsey, Maddalena Ardissino, Vanita R Aroda, Matthew A Cavender, Renato D Lopes, Hussein R Al-Khalidi, Rogelio Braceras, Tanya Gaynor, Lisa A Kaltenbach, Julienne K Kirk, Ildiko Lingvay, Melissa L Magwire, Emily C O'Brien, Jonathan Pak, Rodica Pop-Busui, Caroline R Richardson, Monica Levya, Cagri Senyucel, Laura Webb, Darren K McGuire, Jennifer B Green, Christopher B Granger
Several medications that are proven to reduce cardiovascular events exist for individuals with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease, however they are substantially underused in clinical practice. Clinician, patient, and system-level barriers all contribute to these gaps in care; yet, there is a paucity of high quality, rigorous studies evaluating the role of interventions to increase utilization. The COORDINATE-Diabetes trial randomized 42 cardiology clinics across the United States to either a multifaceted, site-specific intervention focused on evidence-based care for patients with T2DM or standard of care...
October 21, 2022: American Heart Journal
https://read.qxmd.com/read/36259751/cohort-profile-the-esc-eurobservational-research-programme-non-st-segment-elevation-myocardial-infraction-nstemi-registry
#26
JOURNAL ARTICLE
Ramesh Nadarajah, Peter Ludman, Yolande Appelman, Salvatore Brugaletta, Andrzej Budaj, Hector Bueno, Kurt Huber, Vijay Kunadian, Sergio Leonardi, Maddalena Lettino, Dejan Milasinovic, Chris P Gale
AIMS: The European Society of Cardiology (ESC) EURObservational Research Programme (EORP) Non-ST-segment elevation myocardial infarction (NSTEMI) Registry aims to identify international patterns in NSTEMI management in clinical practice and outcomes against the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without ST-segment-elevation. METHODS AND RESULTS: Consecutive hospitalised adult NSTEMI patients (n = 3620) were enrolled between 11 March 2019 to 6 March 2021, and individual patient data prospectively collected at 287 centres in 59 participating countries during a two-week enrolment period per centre...
October 19, 2022: European Heart Journal. Quality of Care & Clinical Outcomes
https://read.qxmd.com/read/36241580/antiplatelet-therapy-at-discharge-and-long-term-prognosis-in-takotsubo-syndrome-insights-from-the-spanish-national-registry-retako
#27
JOURNAL ARTICLE
Eduardo Pereyra, Diego Fernández-Rodríguez, Silvia González-Sucarrats, Manuel Almendro-Delia, Agustín Martín, Irene Martin de Miguel, Mireia Andrés, Alberto Duran-Cambra, Alejandro Sánchez-Grande-Flecha, Fernando Worner-Diz, Iván J Núñez-Gil
INTRODUCTION: Endothelial dysfunction and platelet activation have been highlighted as possible mediators in Takotsubo syndrome (TTS). Nevertheless, to date, evidence on the usefulness of antiplatelet therapy in TTS remains controversial. The aim of our study is to evaluate long-term prognosis in TTS patients treated with antiplatelet therapy (APT) at hospitalization discharge. MATERIAL AND METHODS: An ambispective cohort study from the Spanish National Takotsubo Registry database was performed (June 2002 to March 2017)...
October 11, 2022: Portuguese Journal of Cardiology: An Official Journal of the Portuguese Society of Cardiology
https://read.qxmd.com/read/36193931/comparison-of-pharmacy-refill-data-with-chemical-adherence-testing-in-assessing-medication-nonadherence-in-a-safety-net-hospital-setting
#28
JOURNAL ARTICLE
David Osula, Bryan Wu, Kevin Schesing, Sandeep R Das, Elizabeth Moss, Kristin Alvarez, Christopher Clark, Ethan A Halm, Nancy J Brown, Wanpen Vongpatanasin
Background Pharmacy fill data are a practical tool for assessing medication nonadherence. However, previous studies have not compared the accuracy of pharmacy fill data to measurement of plasma drug levels, or chemical adherence testing (CAT). Methods and Results We performed a cross-sectional study in patients with uncontrolled hypertension in outpatient clinics in a safety net health system. Plasma samples were obtained for measurement of common cardiovascular drugs, including calcium channel blockers, thiazide diuretics, beta blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and statins, using liquid chromatography mass spectrometry...
October 4, 2022: Journal of the American Heart Association
https://read.qxmd.com/read/36179904/higher-mortality-in-acute-coronary-syndrome-patients-without-standard-modifiable-risk-factors-results-from-a-global-meta-analysis-of-1-285-722-patients
#29
JOURNAL ARTICLE
Gwyneth Kong, Yip Han Chin, Bryan Chong, Rachel Sze Jen Goh, Oliver Zi Hern Lim, Cheng Han Ng, Mark Muthiah, Roger Foo, Stephen T Vernon, Poay Huan Loh, Mark Y Chan, Nicholas W S Chew, Gemma A Figtree
BACKGROUND: Standard modifiable cardiovascular risk factors (SMuRF), comprising diabetes, hyperlipidemia, hypertension, and smoking, are used for risk stratification in acute coronary syndrome (ACS). Recent studies showed an increasing proportion of SMuRF-less ACS patients. METHODS: Embase, Medline and Pubmed were searched for studies comparing SMuRF-less and SMuRF patients with first presentation of ACS. We conducted single-arm analyses to determine the proportion of SMuRF-less patients in the ACS cohort, and compared the clinical presentation and outcomes of these patients...
January 15, 2023: International Journal of Cardiology
https://read.qxmd.com/read/36172938/clinical-practice-variations-in-the-management-of-ischemia-with-no-obstructive-coronary-artery-disease
#30
JOURNAL ARTICLE
Judy M Luu, Janet Wei, Chrisandra L Shufelt, Anum Asif, Benita Tjoe, Paul Theriot, C Noel Bairey Merz
Background Ischemia with no obstructive coronary artery disease is a condition associated with major adverse cardiovascular outcomes. To date, there are no specific American Heart Association or American College of Cardiology guidelines. The objective of this survey is to better understand the clinical practice and knowledge gaps that exist nationally. Methods and Results Participant-specific links for a survey with 11 questions and 3 reminders were sent between September and October 2020 to the American College of Cardiology CardioSurve Panel...
September 29, 2022: Journal of the American Heart Association
https://read.qxmd.com/read/36116032/adherence-with-cardiovascular-medications-and-the-outcomes-in-patients-with-coronary-arterial-disease-real-world-evidence
#31
JOURNAL ARTICLE
Chen Chen, Xiaoqing Li, Yuhao Su, Zhigang You, Rong Wan, Kui Hong
BACKGROUND: Cardiovascular medications are vital for the secondary prevention of coronary arterial disease (CAD). However, the effect of cardiovascular medication may depend on the optimal adherence of the patients. This meta-analysis aims to determine the magnitude of adherence to vascular medications that influences the absolute and relative risks (RRs) of mortality in patients with CAD in real-world settings. METHODS: The Cochrane Library, PubMed, and EMBASE databases were searched through March 1, 2022...
September 18, 2022: Clinical Cardiology
https://read.qxmd.com/read/35991714/optimal-cardiovascular-medical-therapy-current-guidelines-and-new-developments
#32
JOURNAL ARTICLE
Shirley Cotty Reed, Nikita Dhir, R Jay Widmer
Coronary artery disease is a leading cause of mortality worldwide, and patients with obstructive coronary artery disease require optimal cardiovascular medical therapy along with lifestyle modification for secondary prevention of future cardiac events. Optimal medical therapy includes antiplatelet agents, high-intensity statins, beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, aldosterone antagonists, and calcium channel blockers. There are differences in the medical therapy guidelines of the American Heart Association/American College of Cardiology and the European Society of Cardiology...
2022: Proceedings of the Baylor University Medical Center
https://read.qxmd.com/read/35987312/impact-of-secondary-prevention-medical-therapies-on-outcomes-of-patients-suffering-from-myocardial-infarction-with-nonobstructive-coronary-artery-disease-minoca-a-meta-analysis
#33
REVIEW
Ovidio De Filippo, Caterina Russo, Rossella Manai, Irene Borzillo, Federica Savoca, Guglielmo Gallone, Francesco Bruno, Mahmood Ahmad, Gaetano Maria De Ferrari, Fabrizio D'Ascenzo
AIMS: To assess the impact of secondary prevention medical therapies (statins, ACE-inhibitors/Angiotensin Receptor Blockers (ARB), beta-blockers (BB) and Dual Antiplatelet Therapy (DAPT)) on outcomes of patients with myocardial infarction with nonobstructive coronary artery disease (MINOCA). METHODS: Five adjusted observational studies encompassing 10,546 were included in this meta-analysis. All-cause death was the primary endpoint, while Major Adverse Cardiovascular Events (MACE) and acute myocardial infarction (AMI) were the secondary endpoints...
December 1, 2022: International Journal of Cardiology
https://read.qxmd.com/read/35876409/mortality-and-cardiovascular-outcomes-in-patients-presenting-with-non-st-elevation-myocardial-infarction-despite-no-standard-modifiable-risk-factors-results-from-the-swedeheart-registry
#34
JOURNAL ARTICLE
Gemma A Figtree, Stephen T Vernon, Nermin Hadziosmanovic, Johan Sundström, Joakim Alfredsson, Stephen J Nicholls, Clara K Chow, Peter Psaltis, Helge Røsjø, Margrét Leósdóttir, Emil Hagström
Background A significant proportion of patients with ST-segment-elevation myocardial infarction (MI) have no standard modifiable cardiovascular risk factors (SMuRFs) and have unexpected worse 30-day outcomes compared with those with SMuRFs. The aim of this article is to examine outcomes of patients with non-ST-segment-elevation MI in the absence of SMuRFs. Methods and Results Presenting features, management, and outcomes of patients with non-ST-segment-elevation MI without SmuRFs (hypertension, diabetes, hypercholesterolemia, smoking) were compared with those with SmuRFs in the Swedish MI registry SWEDEHEART (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies; 2005-2018)...
August 2, 2022: Journal of the American Heart Association
https://read.qxmd.com/read/35709853/underutilization-of-medical-management-of-peripheral-artery-disease-among-patients-with-claudication-undergoing-lower-extremity-bypass
#35
JOURNAL ARTICLE
Ryan Howard, Jeremy Albright, Chloe Powell, Nicholas Osborne, Matthew Corriere, Eugene Laveroni, Devraj Sukul, Philip Goodney, Peter Henke
OBJECTIVE: First-line treatment of peripheral artery disease (PAD) involves medical therapy and lifestyle modification. Multiple professional organizations such as the Society for Vascular Surgery and the American Heart Association/American College of Cardiology make Class I recommendations for medical management including antiplatelet, statin, antihypertensive, and cilostazol medications, as well as lifestyle therapy including exercise and smoking cessation. Although evidence supports up-front medical and lifestyle management prior to surgical intervention, it is unclear how well this occurs in contemporary clinical practice...
October 2022: Journal of Vascular Surgery
https://read.qxmd.com/read/35610067/impact-of-statins-in-patients-with-vasospastic-angina-a-multicenter-registry-study-of-the-japanese-coronary-spasm-association
#36
MULTICENTER STUDY
Hiroyoshi Mori, Jun Takahashi, Koichi Sato, Satoshi Miyata, Yusuke Takagi, Ryusuke Tsunoda, Tetsuya Sumiyoshi, Motoyuki Matsui, Yasuhiko Tanabe, Shozo Sueda, Shin-Ichi Momomura, Koichi Kaikita, Satoshi Yasuda, Hisao Ogawa, Hiroaki Shimokawa, Hiroshi Suzuki
BACKGROUND: Statins are generally used for patients with coronary artery disease. However, the impact of statins in patients with vasospastic angina (VSA) is not fully understood. METHODS: In a multicenter registry study of the Japanese Coronary Spasm Association (n = 1429), patients with or without statins were compared. The primary endpoint was major adverse cardiac events (MACEs), defined as cardiac death, non-fatal myocardial infarction, unstable angina, heart failure, and appropriate implantable cardioverter defibrillator shock...
September 2022: Journal of Cardiology
https://read.qxmd.com/read/35020077/implementation-of-clinical-audit-to-improve-adherence-to-guideline-recommended-therapy-in-acute-coronary-syndrome
#37
JOURNAL ARTICLE
Nimmy Elizabeth George, Aashiq Ahamed Shukkoor, Noel Joseph, Ramasamy Palanimuthu, Tamilarasu Kaliappan, Rajendiran Gopalan
BACKGROUND: Despite global consensus on the management of acute coronary syndrome (ACS), implementation of strategies to improve adherence of guideline-directed medical therapy (GDMT) remains sub-optimal, especially in developing countries. Thus, we aimed to assess the effect of clinical pharmacist-led clinical audit to improve the compliance of discharge prescriptions in patients admitted with ACS. It is a prospective clinical audit of ACS patients which was carried out for 12 months...
January 12, 2022: Egyptian Heart Journal: EHJ
https://read.qxmd.com/read/34897399/addressing-disparities-of-care-in-non-st-segment-elevation-myocardial-infarction-patients-without-standard-modifiable-risk-factors-insights-from-a-nationwide-cohort-study
#38
JOURNAL ARTICLE
Saadiq M Moledina, Muhammad Rashid, James Nolan, Kazuhiro Nakao, Louise Y Sun, Poonam Velagapudi, Stephen B Wilton, Annabelle Santos Volgman, Chris P Gale, Mamas A Mamas
AIMS: The importance of standard modifiable cardiovascular risk factors (SMuRFs) in preventing non-ST-segment elevation myocardial infarction (NSTEMI) is established. However, NSTEMI may present in the absence of SMuRFs, and little is known about their outcomes. METHODS AND RESULTS: We analysed 176 083 adult (≥18 years) hospitalizations with NSTEMI using data from the United Kingdom (UK) Myocardial Infarction National Audit Project (MINAP). Clinical characteristics and all-cause in-hospital mortality were analysed according to SMuRF status, with 135 223 patients presenting with at least one of diabetes, hypertension, hypercholesterolaemia, or current smoking status and 40 860 patients without any SMuRFs...
May 25, 2022: European Journal of Preventive Cardiology
https://read.qxmd.com/read/34713782/analysis-of-influence-of-background-therapy-for-comorbidities-in-the-period-before-infection-on-the-risk-of-the-lethal-covid-outcome-data-from-the-international-activ-sars-cov-2-registry-%C3%A2-analysis-of-chronic-non-infectious-diseases-dynamics-after-covid-19
#39
MULTICENTER STUDY
E I Tarlovskaya, A G Arutyunov, A O Konradi, Yu M Lopatin, A P Rebrov, S N Tereshchenko, A I Chesnikova, H G Hayrapetyan, A P Babin, I G Bakulin, N V Bakulina, L A Balykova, A S Blagonravova, M V Boldina, A R Vaisberg, A S Galyavich, V V Gomonova, N Yu Grigorieva, I V Gubareva, I V Demko, A V Evzerikhina, A V Zharkov, U K Kamilova, Z F Kim, T Yu Kuznetsova, N V Lareva, E V Makarova, S V Malchikova, S V Nedogoda, M M Petrova, I G Pochinka, K V Protasov, D N Protsenko, D Yu Ruzanau, S A Sayganov, A S Sarybaev, N M Selezneva, A B Sugraliev, I V Fomin, O V Khlynova, O Yu Chizhova, I I Shaposhnik, D A Shсukarev, A K Abdrahmanova, S A Avetisian, H G Avoyan, K K Azarian, G T Aimakhanova, D A Ayipova, A Ch Akunov, M K Alieva, A V Aparkina, O R Aruslanova, E Yu Ashina, O Yu Badina, O Yu Barisheva, A S Batchayeva, A M Bitieva, I U Bikhteyev, N A Borodulina, M V Bragin, A M Budu, L A Burygina, G A Bykova, K R Vagapova, D D Varlamova, N N Vezikova, E A Verbitskaya, O E Vilkova, E A Vinnikova, V V Vustina, E A Gаlova, V V Genkel, E I Gorshenina, R V Gostishev, E V Grigorieva, E Yu Gubareva, G M Dabylova, A I Demchenko, O Yu Dolgikh, M Y Duyshobayev, D S Evdokimov, K E Egorova, A N Ermilova, A E Zheldybayeva, N V Zarechnova, Yu D Zimina, S Yu Ivanova, E Yu Ivanchenko, M V Ilina, M V Kazakovtseva, E V Kazymova, Yu S Kalinina, N A Kamardina, A M Karachenova, I A Karetnikov, N A Karoli, O V Karpov, M Kh Karsiev, D S Кaskaeva, K F Kasymova, Zh B Kerimbekova, A Sh Kerimova, E S Kim, N V Kiseleva, D A Klimenko, A V Klimova, O V Kovalishena, E V Kolmakova, T P Kolchinskaya, M I Kolyadich, O V Kondriakova, M P Konoval, D Yu Konstantinov, E A Konstantinova, V A Kordukova, E V Koroleva, A Yu Kraposhina, T V Kriukova, A S Kuznetsova, T Yu Kuzmina, K V Kuzmichev, Ch K Kulchoroeva, T V Kuprina, I M Kouranova, L V Kurenkova, N Yu Kurchugina, N A Kushubakova, V I Levankova, M Е Levin, N A Lyubavina, N A Magdeyeva, K V Mazalov, V I Majseenko, A S Makarova, A M Maripov, A A Marusina, E S Melnikov, N B Moiseenko, F N Muradova, R G Muradyan, A O Myshak, N M Nikitina, B B Ogurlieva, A A Odegova, Yu M Omarova, N A Omurzakova, Sh O Ospanova, E V Pahomova, L D Petrov, S S Plastinina, V A Pogrebetskaya, D S Polyakov, E V Ponomarenko, L L Popova, N A Prokofeva, I A Pudova, N A Rakov, A N Rakhimov, N A Rozanova, S Serikbolkyzy, A A Simonov, V V Skachkova, D V Soloveva, I A Soloveva, F M Sokhova, A K Subbotin, I M Sukhomlinova, A G Sushilova, D R Tagayeva, Yu V Titojkina, E P Tikhonova, D S Tokmin, A A Tolmacheva, M S Torgunakova, K V Trenogina, N A Trostianetckaia, D A Trofimov, A A Tulichev, A T Tursunova, N D Ulanova, O V Fatenkov, O V Fedorishina, T S Fil, I Yu Fomina, I S Fominova, I A Frolova, S M Tsvinger, V V Tsoma, M B Cholponbaeva, T I Chudinovskikh, O A Shevchenko, T V Sheshina, E A Shishkina, K Yu Shishkov, S Yu Sherbakov, E A Yausheva, Sh N Musaelian, Yu N Belenkov, G P Arutyunov
Aim      To study the effect of regular drug therapy for cardiovascular and other diseases preceding the COVID-19 infection on severity and outcome of COVID-19 based on data of the ACTIVE (Analysis of dynamics of Comorbidities in paTIents who surVived SARS-CoV-2 infEction) registry.Material and methods  The ACTIVE registry was created at the initiative of the Eurasian Association of Therapists. The registry includes 5 808 male and female patients diagnosed with COVID-19 treated in a hospital or at home with a due protection of patients' privacy (data of nasal and throat smears; antibody titer; typical CT imaging features)...
September 30, 2021: Kardiologiia
https://read.qxmd.com/read/34713706/lifetime-risk-of-heart-failure-and-trends-in-incidence-rates-among-individuals-with-type-2-diabetes-between-1995-and-2018
#40
JOURNAL ARTICLE
Brian Schwartz, Colin Pierce, Ramachandran S Vasan, Morten Schou, Michel Ibrahim, Kevin Monahan, Asya Lyass, Morten Malmborg, Gunnar H Gislason, Lars Køber, Christian Torp-Pedersen, Charlotte Andersson
Background There are limited data on the lifetime risk of heart failure (HF) in people with type 2 diabetes and how incidence has changed over time. We estimated the cumulative incidence and incidence rates of HF among Danish adults with type 2 diabetes between 1995 and 2018 using nationwide data. Methods and Results In total, 398 422 patients (49% women) with type 2 diabetes were identified. During follow-up, 36 400 (9%) were diagnosed with HF and 121 459 (30%) were censored due to death. Using the Aalen-Johansen estimators, accounting for the risk of death, the estimated residual lifetime risk of HF at age 50 years was calculated as 24% (95% CI 22%-27%) in women and 27% (25%-28%) in men...
October 29, 2021: Journal of the American Heart Association
keyword
keyword
117779
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.